Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Agomab Therapeutics Closes Acquisition of Origo Biopharma.

Document Cited in Related
Vincent

MANews-(C)2009-2021

Belgium-based biotechnology company Agomab Therapeutics NV has closed the acquisition of Spanish clinical-stage biotechnology company Origo Biopharma S.L., the company said.

Origo Biopharma is developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-ÃY) pathway for the treatment of fibrosis-related disorders.

The combined organization will focus on translating growth factor signaling pathways into innovative therapies.

Agomab's hepatocyte growth factor -targeting monoclonal antibodies together with Origo's small molecule programs create a rich clinical pipeline of therapeutics that address fibrosis and organ failure in multiple therapeutic areas.

Origo Biopharma is a Spanish clinical-stage, privately held biotechnology company with research facilities in Touro (Galicia) and corporate offices in Barcelona.

The company has developed novel organ-restricted small molecule entities to maximize the potential of local TGF-ÃY inhibition while avoiding systemic toxicities.

Origo's lead program, ORG-129, is a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial to evaluate safety, tolerability and pharmacokinetics. The first target indication is fibrostenotic Crohn's...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT